Question 1

What is the Ipamorelin/CJC-1295 combination?

Accepted Answer

This combination pairs two distinct growth hormone secretagogue peptides. Ipamorelin (a GHS-R1a agonist) and CJC-1295 without DAC (a GHRH analog), for multi-pathway research in controlled settings.

Question 2

Why study these peptides together?

Accepted Answer

Researchers examine this combination to investigate potential synergistic signaling between GHS-R1a and GHRH receptor pathways in preclinical models of dual-pathway activation.

Question 3

How are the two peptides characterized?

Accepted Answer

Each peptide is independently verified for purity and identity before combination. Both undergo 8 rounds of analytical testing with full COA documentation.

Question 4

What research models use this combination?

Accepted Answer

This combination is examined in preclinical models studying coordinated receptor activation, signaling pathway crosstalk, and temporal dynamics of secretagogue activity.

Question 5

How is product quality verified?

Accepted Answer

Every batch undergoes 8 rounds of independent analytical testing: HPLC purity analysis, mass spectrometry identity confirmation, net peptide content, endotoxin screening, sterility verification, heavy metals, trace contaminant analysis, and multi-vial conformity. Full Certificates of Analysis documenting all results are available for each production lot.

SKU	IP-CJC/IPA-10
Intended Use	For laboratory research use only. Not for human consumption.

Ipamorelin/CJC-1295 (no DAC) 5MG/5MG

Certificates of Analysis

You May Also Like

Kisspeptin 10MG

KLOW Blend 80MG

KPV

LL-37